Federated Hermes Inc. Has $3.34 Million Holdings in Haemonetics Co. (NYSE:HAE)

Federated Hermes Inc. lessened its holdings in shares of Haemonetics Co. (NYSE:HAE) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,092 shares of the medical instruments supplier’s stock after selling 1,887 shares during the quarter. Federated Hermes Inc.’s holdings in Haemonetics were worth $3,343,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Keene & Associates Inc. increased its holdings in Haemonetics by 3.1% during the 4th quarter. Keene & Associates Inc. now owns 8,780 shares of the medical instruments supplier’s stock worth $751,000 after purchasing an additional 268 shares in the last quarter. Louisiana State Employees Retirement System bought a new position in Haemonetics during the 4th quarter worth about $1,223,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Haemonetics by 3.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock worth $1,956,000 after purchasing an additional 838 shares in the last quarter. ABLE Financial Group LLC increased its holdings in Haemonetics by 28.4% during the 4th quarter. ABLE Financial Group LLC now owns 7,251 shares of the medical instruments supplier’s stock worth $620,000 after purchasing an additional 1,606 shares in the last quarter. Finally, LVZ Inc. increased its holdings in Haemonetics by 9.4% during the 4th quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock worth $257,000 after purchasing an additional 259 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Shares of NYSE HAE opened at $90.99 on Friday. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of 36.99, a PEG ratio of 2.07 and a beta of 0.36. The business has a 50-day moving average of $80.40 and a 200-day moving average of $82.61. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $95.26.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter last year, the company posted $0.85 earnings per share. Haemonetics’s quarterly revenue was up 10.1% on a year-over-year basis. As a group, sell-side analysts predict that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HAE shares. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Barrington Research restated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a report on Friday, April 12th. Finally, TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.